Cart
sales@molnova.com
BMS-754807
CAS No. 1001350-96-4
BMS-754807 ( BMS 754807;BMS754807 )
Catalog No. M10014 CAS No. 1001350-96-4
BMS-754807 (BMS 754807, BMS754807)is a potent, reversible, orally active inhibitor of IGF-1R/Insulin receptor with IC50 of 1.8 and 1.7 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 58 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 152 | In Stock |
|
| 25MG | 311 | In Stock |
|
| 50MG | 509 | In Stock |
|
| 100MG | 732 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-754807
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-754807 (BMS 754807, BMS754807)is a potent, reversible, orally active inhibitor of IGF-1R/Insulin receptor with IC50 of 1.8 and 1.7 nM, respectively.
-
DescriptionBMS-754807 (BMS 754807, BMS754807)is a potent, reversible, orally active inhibitor of IGF-1R/Insulin receptor with IC50 of 1.8 and 1.7 nM, respectively; shows additional off-target activities Met, RON, TrkA, TrkB, AurA, and AurB (IC50=5-45 nM) in a panel of 27 kinases; inhibits the growth of a broad range of human tumor types in vitro (IC50=5-365 nM), induces PARP and Caspase 3 cleavage, promotes apoptosis; exhibits tumor growth inhibition in xenograft tumor models.Breast Cancer Phase 2 Discontinued
-
SynonymsBMS 754807;BMS754807
-
PathwayAngiogenesis
-
TargetIGF-1R
-
RecptorIGF-1R;InsulinReceptor;Met;TrkA;TrkB
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1001350-96-4
-
Formula Weight461.49
-
Molecular FormulaC23H24FN9O
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC[C@]1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F
-
Chemical Name2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wittman MD, et al. Mol Cancer Ther. 2009 Dec;8(12):3341-9.
2. Carboni JM, et al. Mol Cancer Ther. 2009 Dec;8(12):3341-9.
3. Dinchuk JE, et al. Endocrinology. 2010 Sep;151(9):4123-32.
4. Huang F, et al. Cancer Res. 2010 Sep 15;70(18):7221-31.
2. Carboni JM, et al. Mol Cancer Ther. 2009 Dec;8(12):3341-9.
3. Dinchuk JE, et al. Endocrinology. 2010 Sep;151(9):4123-32.
4. Huang F, et al. Cancer Res. 2010 Sep 15;70(18):7221-31.
molnova catalog
related products
-
HNMPA
HNMPA is an inhibitor of insulin receptor tyrosine kinase and inhibits the serine and tyrosine autophosphorylation of human insulin receptor.
-
NT157
NT157 is a small molecule tyrphostin targeting IRS protein and has the potential to inhibit IGF-1R and STAT3 signaling pathways in TME cancer cells and stromal cells, resulting in decreased cancer cell survival.
-
LMPTP INHIBITOR 1 hy...
LMPTP INHIBITOR 1 is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an IC50 of 0.8 μM LMPTP-A.
